161 related articles for article (PubMed ID: 36919249)
1. Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy.
Salim M; Ramirez G; Clulow AJ; Hawley A; Boyd BJ
Mol Pharm; 2023 Apr; 20(4):2256-2265. PubMed ID: 36919249
[TBL] [Abstract][Full Text] [Related]
2. Low-Frequency Raman Scattering Spectroscopy as an Accessible Approach to Understand Drug Solubilization in Milk-Based Formulations during Digestion.
Salim M; Fraser-Miller SJ; Be Rziņš KR; Sutton JJ; Ramirez G; Clulow AJ; Hawley A; Beilles S; Gordon KC; Boyd BJ
Mol Pharm; 2020 Mar; 17(3):885-899. PubMed ID: 32011151
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
4. Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion.
Salim M; Ramirez G; Peng KY; Clulow AJ; Hawley A; Ramachandruni H; Beilles S; Boyd BJ
Mol Pharm; 2020 Jul; 17(7):2749-2759. PubMed ID: 32574056
[TBL] [Abstract][Full Text] [Related]
5. Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria.
Salim M; Khan J; Ramirez G; Murshed M; Clulow AJ; Hawley A; Ramachandruni H; Beilles S; Boyd BJ
Mol Pharm; 2019 Apr; 16(4):1658-1668. PubMed ID: 30830789
[TBL] [Abstract][Full Text] [Related]
6. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
Tanaka Y; Doi H; Katano T; Kasaoka S
Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
[TBL] [Abstract][Full Text] [Related]
7. Interactions of Artefenomel (OZ439) with Milk during Digestion: Insights into Digestion-Driven Solubilization and Polymorphic Transformations.
Salim M; Khan J; Ramirez G; Clulow AJ; Hawley A; Ramachandruni H; Boyd BJ
Mol Pharm; 2018 Aug; 15(8):3535-3544. PubMed ID: 29932660
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
9. In Operando Analysis of Milk-Based Oral Formulations during Digestion Using Synchrotron Small-Angle X-ray Scattering Coupled to Low-Frequency Raman Spectroscopy.
Be Rziņš KR; Meiland P; Aljabbari A; Boyd BJ
Anal Chem; 2024 Jan; 96(2):887-894. PubMed ID: 38175633
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
11. Solid-State Behavior and Solubilization of Flash Nanoprecipitated Clofazimine Particles during the Dispersion and Digestion of Milk-Based Formulations.
Salim M; Ramirez G; Clulow AJ; Zhang Y; Ristroph KD; Feng J; McManus SA; Hawley A; Prud'homme RK; Boyd BJ
Mol Pharm; 2019 Jun; 16(6):2755-2765. PubMed ID: 31038976
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
[TBL] [Abstract][Full Text] [Related]
13. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
14. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
[TBL] [Abstract][Full Text] [Related]
15. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209
[TBL] [Abstract][Full Text] [Related]
16. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
[TBL] [Abstract][Full Text] [Related]
17. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
Ramos JT; De José MI; Dueñas J; Fortuny C; González-Montero R; Mellado MJ; Mur A; Navarro M; Otero C; Pocheville I; Muñoz-Fernández MA; Cabrero E;
Pediatr Infect Dis J; 2005 Oct; 24(10):867-73. PubMed ID: 16220083
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.
Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN;
Medicine (Baltimore); 2020 Sep; 99(39):e22352. PubMed ID: 32991450
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P
Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466
[TBL] [Abstract][Full Text] [Related]
20. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
